Med24
overweight-obesity 16. 9. 2025 • 2 min read • Endocrine practice : official journal of the American College of Endocrinology and the American Asso

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update

Objective This 2025 consensus statement provides evidence-based visual guidance in graphic algorithms and a summary of evidence to assist health care professionals and adults with obesity and adiposity-based chronic disease (ABCD) in shared decision making to improve care and achieve health goals. Methods AACE...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This 2025 consensus statement provides visual guidance in graphic algorithms to assist healthcare professionals and adults with obesity and adiposity-based chronic disease (ABCD) in shared decision-making. The algorithm updates the 2016 AACE algorithm, aligning it with related clinical guidance. Surgical and procedural therapies for obesity treatment, as well as care for pediatric-aged patients, are outside the scope of this algorithm. The algorithm includes eleven sections focusing on person-centered and complication-centric management of obesity/ABCD. It addresses screening and diagnosis, encompassing anthropometric and clinical components for diagnosis. An individualized treatment plan, therapeutic goals, and follow-up are included, alongside considerations for response to therapy and weight-loss targets. Behavioral/lifestyle therapy for individuals with obesity/ABCD is also addressed. The algorithm outlines hierarchies of preferred medications for complication-centric care, lower-cost pharmacologic step therapy, and individualization of medication therapy. It references medications approved by the U.S. Food and Drug Administration. The algorithm underscores that ABCD is a complex, chronic disease requiring long-term treatment and care. Emphasis is placed on optimizing health rather than solely weight reduction, and achieving clinical goals beyond a singular focus on body mass index. Individualized interventions, tailored to disease severity or stage, are recommended. Equality of care and reducing weight bias and stigma through a biopsychosocial chronic care model are critical components of this clinical guidance statement.

Sponsored content

Original Scientific Source
Endocrine practice : official journal of the American College of Endocrinology and the American Asso
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement